Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    Peppermint

    go.drugbank.com/drugs/DB10984
    Approved

    Peppermint allergenic extract is used in allergenic testing.

  2. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market

  3. Drug

    Oxomemazine

    go.drugbank.com/drugs/DB13820
    Investigational

    Oxomemazine is a phenothiazine derivative.

  4. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  5. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    ’s and Schizophrenia, an unmet medical need. … SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  6. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.

  7. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  8. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

  9. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.

  10. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants